The combination of belzutifan (Welireg) and lenvatinib (Lenvima) led to superior outcomes, compared with cabozantinib (Cabometyx), in a phase 3 trial of patients with advanced clear cell renal cell ...
Allogene Therapeutics (ALLO) will concurrently present new data from the Phase 1 TRAVERSE trial in an oral presentation at the 2024 International Kidney Cancer Symposium and a poster session at The ...
Even with the increase of immunotherapy utilization to treat patients with advanced renal cell carcinoma, more research is needed to determine in which order to administer it as later lines of therapy ...
Diagnosed With Advanced Renal Cell Carcinoma: Why You May Want a Second Opinion, and How to Find One
Many people with cancer can benefit from a second medical opinion. Those with advanced renal cell carcinoma (RCC), who are likely considering multiple treatment options, if not combinations of ...
MADRID -- Treatment with the hypoxia-inducible factor 2α (HIF-2α) inhibitor belzutifan (Welireg) in advanced, heavily pretreated kidney cancer led to superior outcomes when compared with an older ...
The approval of belzutifan, an oral hypoxia-inducible factor-2 alpha inhibitor, provides a new option for patients with advanced renal cell carcinoma (RCC) following treatment with a programmed death ...
Interim analysis showed pembrolizumab/lenvatinib plus belzutifan failed to improve OS or reduce progression/death risk versus pembrolizumab/lenvatinib in first-line ...
In the second part of a 2-part series, Rana R. McKay, MD, associate professor of Medicine and Urology, Moores Cancer Center, University of California San Diego, discusses second-line treatment options ...
RAHWAY, N.J. & NUTLEY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today announced results from the Phase 3 LITESPARK-012 trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results